APOE and Alzheimer disease: Also, cross‐validated ROC curves (Figure 5) showed that among APOE ε4 carriers, the area under the curve (AUC) of Model 1 to discriminate AD patients from NC individuals was 0.78 (95% CI [0.69, 0.87]), the AUC of Model 2 was 0.88 (95% CI [0.81, 0.95]), and the AUC of Model 3 was up to 0.94 (95% CI [0.89, 0.98]).